方盛制药：妇科止血消痛颗粒药物临床试验获批准

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) announced that its subsidiary, Guangdong Fangsheng R&D Pharmaceutical Co., Ltd. (referred to as "Fangsheng R&D"), has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for its innovative traditional Chinese medicine project, the Gynecological Hemostasis and Pain Relief Granules [1] Group 1 - The National Medical Products Administration has approved the clinical trial for the product, allowing the company to proceed with Phase II and III clinical trials after further refining the clinical trial protocol [1]